Obinutuzumab for lupus kidney disease (membranous type)
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a medication called obinutuzumab for people with lupus-related kidney disease, specifically a type called pure membranous nephropathy. The goal is to see if it helps reduce protein leaking into the urine and improves kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) and a kidney biopsy confirmed a type called pure membranous lupus nephritis within the last year.
- You are between 18 and 75 years old.
- You have a high level of protein in your urine (nephrotic range) or it remains above a certain level despite standard treatments.
- You have not used certain medications recently, like rituximab in the past 6 months or other immune-suppressing drugs in the past 2 months.
- Your kidneys are working well enough (eGFR above 30) and not too scarred.
- You agree to use effective contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This trial tests whether adding the drug obinutuzumab to standard therapy (mycophenolate and steroids) helps control lupus-related kidney inflammation better than standard therapy alone. It might reduce kidney damage and improve outcomes for people with active lupus nephritis.
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
This study looks at how well belimumab (Benlysta) works in real-world settings for adults with lupus nephritis (kidney inflammation caused by lupus). If you started belimumab in the past 6–24 months, the researchers will review your medical records to see how your kidney health has changed.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.